← Human Trials & Peer-Reviewed Studies
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03)
Plain-language guide to PMID 23828145 (2014): open-label randomized controlled trial study of Vitamin D, K2, Magnesium and Zinc in 910 subjects.
Key Facts
- PMID
- 23828145
- Journal
- Journal of bone and mineral metabolism
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Tanaka S et al. (16 authors)
- DOI
- 10.1007/s00774-013-0491-4
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Vitamin D, K2, Magnesium and Zinc.
Exclusion criteria are prior warfarin use, secondary osteoporosis or non-osteoporotic metabolic bone diseases, contraindication for vitamin K2 and risedronate, hyper- or hypoparathyroidism, mental disorders, prevalent vertebral fracture at ≥6 sites, severe degenerative spinal deformation between T4 and L4, serious heart, liver, or kidney disease, or bisphosphonate use within the previous 6 months.
Who Took Part
The abstract describes 910 subjects taking part.
The age groups tagged for this paper are older adults, women only.
How the Study Was Run
The researchers set it up as a randomized and open-label study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the subjects and staff both knew the treatment.
What Was Measured
Exclusion criteria are prior warfarin use, secondary osteoporosis or non-osteoporotic metabolic bone diseases, contraindication for vitamin K2 and risedronate, hyper- or hypoparathyroidism, mental disorders, prevalent vertebral fracture at ≥6 sites, severe degenerative spinal deformation between T4 and L4, serious heart, liver, or kidney disease, or bisphosphonate use within the previous 6 months.
PubMed files the paper under topics including Body Mass Index, Bone Density, Bone Density Conservation Agents, Etidronic Acid, Glomerular Filtration Rate, Osteocalcin and Osteoporosis.
What This Means in Plain Language
The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 910 subjects.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2014 (Journal of bone and mineral metabolism), a journal based in Japan.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.